Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bupivacaine + epinephrine** is a fixed-dose injectable combination of the long-acting amide local anesthetic bupivacaine hydrochloride and the vasoconstrictor epinephrine, commonly supplied with epinephrine 1:200,000. Bupivacaine reversibly inhibits voltage-gated sodium channels in peripheral nerves, preventing initiation and propagation of nerve impulses. Epinephrine activates adrenergic receptors, with local alpha-1-mediated vasoconstriction reducing local blood flow, slowing systemic absorption of bupivacaine, prolonging anesthesia, and reducing peak systemic exposure. It is used in adults to produce local or regional anesthesia and analgesia for surgical, dental, diagnostic, therapeutic, and obstetrical procedures through infiltration, peripheral nerve block, caudal block, and epidural block. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67578b56-7540-487e-1fba-481255620e78))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + epinephrine.